AJP - Heart AJP: Heart and Circulatory Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (January 19, 2007). doi:10.1152/ajpheart.00649.2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/5/H2467    most recent
00649.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhande, R.
Right arrow Articles by Karsan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhande, R.
Right arrow Articles by Karsan, A.
Submitted on June 16, 2006
Accepted on January 17, 2007

Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-{kappa}B-independent upregulation of Bcl-XL

Rachel Zhande1 and Aly Karsan2*

1 Pathology and Laboratory Medicine and Medical Biophysics, University of BC and BC Cancer Agency, Vancouver, Canada
2 Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, Canada; Pathology and Laboratory Medicine and Medical Biophysics, University of BC and BC Cancer Agency, Vancouver, Canada

* To whom correspondence should be addressed. E-mail: akarsan{at}bccrc.ca.

Erythropoietin (EPO) regulates the production of red blood cells primarily by preventing apoptosis of erythroid progenitors. More recently however, EPO has emerged as a major cytoprotective cytokine in several non-hemopoietic tissues in the setting of stress or injury. The underlying mechanisms of the protective responses of EPO have not been fully defined. Here we show that EPO triggers a phosphatidylinositol 3-kinase-(PI3K) dependent survival pathway that counteracts endothelial cell death. The protection conferred by PI3K relies on the subsequent induction of Bcl-XL, a pro-survival member of the Bcl-2 protein family. In addition, EPO counteracts the upregulation of the pro-apoptotic BH3-only protein, BIM, which is induced by serum withdrawal. EPO also activates extracellular signal-regulated kinase 1 and 2 (ERK1/2) which are involved in a Bcl-XL-independent cytoprotective pathway. EPO caused a prolonged activation of NF-{kappa}B, which was blocked by inhibition of PI3K, but not by inhibition of MAP/ERK kinase (MEK), suggesting that EPO-activated NF-{kappa}B requires PI3K activity. However, the activation of the NF-{kappa}B pathway was not required for the ability of EPO to counteract endothelial apoptosis. Thus, EPO promotes survival of endothelial cells through PI3K-dependent Bcl-XL-induction and BIM regulation, as well as through a separate mechanism involving the ERK pathway.




This article has been cited by other articles:


Home page
Eur Respir JHome page
R. MacRedmond, G. K. Singhera, and D. R. Dorscheid
Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury
Eur. Respir. J., June 1, 2009; 33(6): 1403 - 1414.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
A. M. Whetzel, D. T. Bolick, and C. C. Hedrick
Sphingosine-1-phosphate inhibits high glucose-mediated ERK1/2 action in endothelium through induction of MAP kinase phosphatase-3
Am J Physiol Cell Physiol, February 1, 2009; 296(2): C339 - C345.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.